TFF Pharmaceuticals initiated with a Buy at JonesResearch

JonesResearch analyst Justin Walsh initiated coverage of TFF Pharmaceuticals with a Buy rating and $7 price target. TFF is a clinical stage biopharmaceutical company focused on developing and commercializing drug products using its patented Thin Film Freezing platform, the analyst tells investors in a research note. The firm sees potential for the market to give more credit to the company’s lead assets and technology platform following potentially "sufficient de-risking clinical data" in 2023.